Highlights of This Issue 4683

SPECIAL FEATURES

Location, Location, Location-Makes All the Difference for Hypoxia in Lung Tumors
Amit Maity and Constantinos Koumenis

New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers
Augusto Villanueva, Yujin Hoshida, Sara Toffanin, Anja Lachenmayer, Clara Alsinet, Radoslav Savic, Helena Cornella, and Josep M. Llovet

Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy
Luca Gattinoni, Yun Ji, and Nicholas P. Restifo

Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Carey K. Anders, Eric P. Winer, James M. Ford, Rebecca Dent, Daniel P. Silver, George W. Sledge, and Lisa A. Carey

HUMAN CANCER BIOLOGY

Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin’s Lymphoma via DR7 Oncoprotein
Aurélie Lacroix, Sophie Collot-Teixeira, Laurent Mardivirin, Arnaud Jaccard, Barbara Petit, Christophe Piquet, Franck Sturz, Pierre-Marie Preux, Dominique Bordessoule, and Sylvie Ranger-Rogez

Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance
Yoshitsugu Mitani, Jie Li, Pulivarthi H. Rao, Yi-jue Zhao, Diana Bell, Scott M. Lippman, Randal S. Weber, Carlos Caulin, and Adel K. El-Naggar

Hypoxia Inducible Factor 1α and Hypoxia Inducible Factor 2α Play Distinct and Functionally Overlapping Roles in Oral Squamous Cell Carcinoma
Gui-quan Zhu, Ya-ling Tang, Ling Li, Min Zheng, Jian Jiang, Xiao-yu Li, Si-xiu Chen, and Xin-hua Liang

Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells
Rekha Rao, Srilatha Nalluri, Warren Fiskus, Andrew Savoie, Kathleen M. Buckley, Kyungsou Ho, Ramesh Balusu, Atul Joshi, Veena Coothankandaswamy, Jianguo Tao, Eduardo Sotomayor, Peter Atadja, and Kapil N. Bhalla

Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata
Shuo Yang, Andrew M. Evens, Sheila Prachand, Amareshwar T.K. Singh, Savita Bhalla, Kevin David, and Leo I. Gordon
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Ganitritinibs, in Advanced Prostate Cancer
Byoung Heon Kang, Markus D. Siegelin, Janet Plescia, Christopher M. Raskett, David S. Garlick, Takehiko Dohi, Jane B. Lian, Gary S. Stein, Lucia R. Languino, and Dario C. Altieri

Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting
Cynthia S. Lancaster, Chaoxin Hu, Ryan M. Franke, Kelly K. Filipski, Shelley J. Orwick, Zhaoyuan Chen, Zhili Zuo, Walter J. Loos, and Alex Sparreboom

Superior Efficacy of Tumor Cell Vaccines Grown in Physiologic Oxygen
Michael R. Olin, Brian M. Andersen, David M. Zellmer, Patrick T. Grogan, Flavia E. Popescu, Zhengming Xiong, Colleen L. Forster, Charlie Seiler, Karen S. Santa Cruz, Wei Chen, Bruce R. Blazar, and John R. Ohlfest

Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase 1 Inhibitor
Fabio Pastorino, Monica Loi, Puja Sapra, Pamela Becherini, Michele Cilli, Laura Emonite, Domenico Ribatti, Lee M. Greenberger, Ivan D. Horak, and Mirco Ponzoni

Detailed Distribution of NK012, an SN-38–Incorporating Micelle, in the Liver and Its Potent Antitumor Effects in Mice Bearing Liver Metastases
Amane Takahashi, Nobuhito Ohkohchi, Masahiro Yasunaga, Jun-ichiro Kuroda, Yoshikatsu Koga, Hirotsugu Kemmotsu, Taira Kinoshita, and Yasuhiro Matsumura

Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer

Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics
Edward E. Graves, Marta Vilalta, Ivana K. Cecic, Janine T. Erler, Phuoc T. Tran, Dean Felsher, Leanne Sayles, Alejandro Sweet-Cordero, Quynh-Thu Le, and Amato J. Giaccia

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Carol Peña, Chetan Lathia, Minghua Shan, Bernard Escudier, and Ronald M. Bukowski

Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types
Matthew D. Wilkerson, Xiaoying Yin, Katherine A. Hoadley, Yufeng Liu, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Hayward, Michele C. Haye
ABOUT THE COVER

Preclinical toxicology analysis of Gamitrinibs. Animals carrying prostate cancer xenografts and treated systemically with vehicle or Gamitrinib-TPP (G-TPP) were sacrificed at the end of treatment and organs were collected and analyzed histologically. A representative image of spleen from the vehicle group is shown. For further details, please see the article by Kang and colleagues on page 4779 of this issue.